<DOC>
	<DOCNO>NCT00003585</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining biological therapy chemotherapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness biological therapy plus chemotherapy treating patient metastatic recurrent kidney cancer .</brief_summary>
	<brief_title>Biological Therapy Plus Chemotherapy Treating Patients With Metastatic Recurrent Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate toxic effect , patient tolerance , practicality administer interferon alfa-2b , fluorouracil , interleukin-2 , isotretinoin ( FUNIL-cRa ) patient metastatic and/or recurrent renal cell carcinoma . II . Obtain pilot indication responsiveness patient regimen . III . Evaluate measurement tumor thymidylate synthetase prediction response patient fluorouracil base regimen . OUTLINE : Patients stratify performance status ( 0 vs 1 ) , nephrectomy ( yes v ) , site disease ( pulmonary lymph node metastases vs disease site ) , radiotherapy ( yes v ) , prior adjuvant biologic hormone therapy ( yes v ) . Patients receive intravenous fluorouracil daily 14 day , subcutaneous interferon alfa-2b 3 time week 6 week . Beginning day 15 , patient receive intravenous interleukin-2 , 5 day week oral isotretinoin 2 time day 4 week . Treatment course 6 week , follow 2 week rest period . Treatment continue 4 course absence disease progression unacceptable toxicity . Patients partial complete response may undergo surgical resection . Patients follow every 2 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic and/or recurrent renal cell carcinoma Bidimensionally measurable disease No concurrent brain metastases Patients prior brain metastasis undergone radiation and/or surgery , stable response , confirm MRI , corticosteroid eligible PATIENT CHARACTERISTICS : Age : Not specify Performance status : SWOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No serious illness active infection require antibiotic Not HIV positive No active substance abuse PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior interleukin2 therapy At least 6 month since prior interferon alfa therapy At least 1 month since prior biologic therapy No concurrent biologic therapy ( e.g. , filgrastim sargramostim ) Chemotherapy : At least 6 month since prior fluorouracil therapy At least 1 month since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 1 month since prior endocrine therapy No concurrent hormone therapy No concurrent corticosteroid except inhaled topical Radiotherapy : At least 1 month since prior radiotherapy ( le 25 % bone marrow , must measurable disease outside radiation field ) No concurrent radiotherapy Surgery : At least 3 week since prior surgery Other : No concurrent ongoing therapy investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>